relative to the substitution of biological products.

This bill defines key terms for substituting biological products (like insulin or cancer treatments made from living organisms) in New Hampshire. It specifies that a "biosimilar" is a product highly similar to an original with no meaningful differences in safety or effectiveness, and an "interchangeable" product meets federal standards for safe substitution without requiring a doctor's specific order. These definitions will guide pharmacists when replacing a prescribed biological product with a biosimilar or interchangeable alternative. The bill directly affects pharmacists, healthcare providers, and patients by establishing a clear legal framework for substitution, aligning with federal guidelines.